Overall, this highlights the importance of identifying more effective therapies, including non-AR–targeted options, to treat a broader spectrum of patients with prostate cancer, particularly those with advanced prostate cancer or metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene AR and prostate carcinoma.